The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2018
DOI: 10.2967/jnumed.118.214379
|View full text |Cite
|
Sign up to set email alerts
|

Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
63
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 77 publications
(70 citation statements)
references
References 17 publications
1
63
0
1
Order By: Relevance
“…(a) 68 Ga-PSMA-11 PET/CTcannot evaluate the excretion function of salivary glands. ere is no effective method to reduce PSMA ligand uptake in salivary glands [26]. Further research is warranted.…”
Section: Discussionmentioning
confidence: 99%
“…(a) 68 Ga-PSMA-11 PET/CTcannot evaluate the excretion function of salivary glands. ere is no effective method to reduce PSMA ligand uptake in salivary glands [26]. Further research is warranted.…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, 177 Lu-PSMA-617 has a long half-life, and uptake of 177 Lu-PSMA-617 from the interstitial or intracellular space into the salivary glands is relatively slow (7). Apart from these considerations, labeling of PSMA-targeting antibodies such as J591 instead of small molecules such as PSMA-617 (molecular weight, 150 vs. 1.4 kD, respectively) might be able to lower the PSMA uptake and decrease the risk of sialotoxicity (25,50,51).…”
Section: Discussionmentioning
confidence: 99%
“…Local application of cold compounds or inhibitors of PSMA, such as 2-(phosphonomethyl) pentanedioic acid, has been also investigated (54). Because of the high blood supply of the PGs, systemic absorption from intraparenchymal application of 2-(phosphonomethyl)pentanedioic acid may cause potential inhibition of PSMA-targeted tumor cells, which needs further consideration (25). Gene and stem cell therapy has been suggested to prevent xerostomia and may soon solve the problem (24).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…When patients with metastatic castration-resistant prostate cancer were treated with the a-emitting 225 Ac-PSMA-617, full biochemical responses were observed in some patients, even in those who had not responded to treatment with 177 Lu-PSMA-617 (11). However, severe and irreversible xerostomia significantly limits the potential utility of this promising approach (13).…”
mentioning
confidence: 99%